Collagen Supplements and Menopausal Skin

Skin is not a passive covering. It carries estrogen receptors in both the dermis and the epidermis and behaves, as Zouboulis and colleagues put it in their 2022 review in Climacteric, as an endocrine organ in its own right. Estrogen drives the synthesis of collagen, elastin, and the glycosaminoglycans that hold water in the dermis. When estrogen falls, those production lines slow.

The pace is what catches most women off guard. Brincat and colleagues (1985) put the loss at roughly 30% of skin collagen in the first five years after the final period, then around 2% a year for the next fifteen. A 2025 narrative review by Viscomi and co-authors in the Journal of Cosmetic Dermatology gives a comparable ongoing figure of about 2.1% per postmenopausal year, driven by less circulating estrogen, less produced locally in the skin, and fewer receptors left to respond.

Chronological ageing alone runs closer to 1% a year. That gap is why the years either side of your last period behave as a distinct window — and why the change so often registers as a mismatch, when skin that used to recover from one bad night starts holding the crease into the afternoon.

Those same reviews are careful about what this does not explain. Visible wrinkling tracks sun exposure, chronological age, and skin type more closely than it tracks menopause. The decline is real, and it is one influence among several.

Eaten Collagen Sends a Signal

The intuition behind the category is that you eat collagen and your body carries it upward to patch the losses. Digestion makes that impossible, and understanding why lets you read the claims that follow.

A study by Virgilio et al. traced what actually reaches the bloodstream: not intact collagen, but free amino acids and small di- and tri-peptides, some carrying the hydroxyproline sequences characteristic of collagen. These fragments cross the gut wall via a dedicated transporter, so bioactive pieces do circulate. They are simply not the finished material.

The plausible mechanism is therefore instruction rather than supply. Dierckx and colleagues (2024, Frontiers in Nutrition) exposed cultured skin fibroblasts — the cells that manufacture dermal collagen — to collagen peptides and watched collagen output rise, alongside other matrix proteins. Picture a scrap of a familiar recipe arriving in a kitchen: not the meal, not the ingredients, but enough to start the cooks working. That matters more at 50 than at 30: the shortfall is a production problem inside the dermis, not a shortage of collagen on your plate.

The same study found no straightforward dose-response. Higher peptide concentrations did not yield more collagen, and cells responded as well, or better, to lower amounts. If you have been eyeing a bigger scoop, the cell data does not support the assumption underneath it.

Two limits sit alongside this. Cell work and one absorption trial cannot show that peptides reach living skin at concentrations that matter, and both studies were funded by collagen ingredient manufacturers. A credible mechanism is not evidence that the signal lands.

Pooled Trials of Collagen Supplements

Pu and colleagues (2023, Nutrients) combined 26 randomised controlled trials covering 1,721 participants and found that hydrolysed collagen improved skin hydration and elasticity to a statistically significant degree, with effects that strengthened beyond eight weeks. A 2021 review by de Miranda and co-authors in the International Journal of Dermatology reached similar conclusions across 19 trials, with roughly 90 days described as effective.

The most detailed single trial comes from Reilly and colleagues (2024), who followed 130 people aged 40 to 60 for twelve weeks, using confocal microscopy and ultrasound rather than surface impressions. Against placebo they measured collagen fragmentation down 44.6%, hydration up 13.8%, elasticity up 22.7%, and wrinkle depth down 19.6%. Daily dosing outperformed alternate days, and the gains faded once supplementation stopped.

Then the picture complicates. Myung and Park (2025, American Journal of Medicine) pooled 23 trials, found the familiar improvements overall, then sorted the studies by funder and by rigour. Trials without supplement or pharmaceutical industry funding showed no significant benefit. Higher-quality trials showed none either — the gains came almost entirely from the weaker studies. An industry body has contested how some trials were graded, which is a fair caution rather than a rebuttal.

If an effect that behaves this way makes you sceptical, that scepticism is well placed, though it cuts both ways. Many trials are short, and many combine collagen with vitamin C or hyaluronic acid, so collagen’s own contribution cannot be isolated. Neither “it works” nor “it is useless” is an honest verdict. “Genuinely uncertain, with a moderate signal” is closer.

Almost all the encouraging data comes from mixed-age groups of mostly younger women, measured often on the forearm rather than the face. The exception speaks directly to your situation. Guadanhim and colleagues (2023, Dermatology and Therapy) ran a double-blind, placebo-controlled, factorial trial in 56 postmenopausal women, testing oral collagen, a topical collagen serum, both together, and placebo across six months. On every endpoint — clinical scoring, elasticity, skin thickness, tissue-level markers — nothing beat placebo.

One negative trial in 56 participants does not settle a field, and the women recruited had markedly fragile skin, which may not describe you. But it stands as the only identified randomised trial in a menopausal population, and its result is entirely negative. Claims about collagen supplements for menopausal skin are based on studies involving mostly younger women.

Marine collagen carries a premium the comparative evidence does not earn. In the source-by-source analysis within Pu’s 2023 review, elasticity showed no statistically significant difference between fish, bovine, porcine, and chicken collagen; chicken performed weakest for hydration. Virgilio’s absorption data points the same way at a 10g dose. No trial has randomised participants to marine versus bovine and tracked skin outcomes, so every comparison is indirect — but on present evidence, source is a question of price, diet, and sustainability rather than results.

The safety of the collagen supplements was confirmed during the studies. Adverse events across these trials were rare and mild, although questions regarding efficacy remain unanswered. If you are considering taking collagen supplements, you should discuss two exceptions with your doctor. Collagen is a protein derived from animals, so allergies to the source species are possible, and anyone managing kidney disease or a protein-restricted diet should factor in an additional 10g of protein daily.

Neither “it works” nor “it’s useless” is the honest verdict. “Genuinely uncertain, with a moderate signal” is closer.

What can be said with some confidence: the mechanism is real but indirect, the pooled gains are measurable on instruments and modest in life, the safety record is consistent across the studies that exist, and the effects stop when you stop. What cannot be said: that any of it has been demonstrated in menopausal skin, or that a more expensive source buys a better outcome.

If you enjoy the ritual, the cost sits comfortably in your month and you understand you are buying a plausible hypothesis rather than a proven effect, there is no reason to feel foolish for taking one. If the standing order is quietly straining the household budget, the evidence gives you full permission to cancel it — you are not throwing away a demonstrated benefit, because there is not yet one to throw away.

A supplement does not hand your skin the finished dish. At best it passes along a recipe, and the kitchen does what it can with it. What is worth protecting is your ability to tell the difference between those two claims — because that distinction, more than any single ingredient, is what most of this aisle depends on you not making.